Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Prostatic Neoplasms 4Carcinoma, Renal Cell 4Recurrence 1Prostatic Hyperplasia 1Ovarian Neoplasms 1Neoplasms 1Neoplasm Metastasis 1Mesothelioma 1Kidney Neoplasms 1Fallopian Tube Neoplasms 1Colorectal Neoplasms 1

Interventions

Dutasteride 3acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide 2proxalutamide 1polyphenon E 1mirabegron 1TroVax 1Transurethral Resection of Prostate 1Transurethral Resection of Bladder 1Therapeutics 1Tamsulosin 1Standard of Care 1Risedronic Acid 1Radiotherapy 1Psychiatric Rehabilitation 1Prostatectomy 1Papaverine 1Oxygen 1Nitrous Oxide 1Needles 1Microspheres 1Lycopene 1Levofloxacin 1Finasteride 1Electroacupuncture 1Doxazosin 1Docetaxel 1Diclofenac 1Dexmedetomidine 1Cystoscopy 1Celecoxib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Prostatic Hyperplasia × TroVax × Clear all
NCT01194960 2020-10-19

TroVax® In Subjects With Hormone Refractory Prostate Cancer (HRPC)

Oxford BioMedica

Phase 2 Terminated
25 enrolled
Genitourinary

Prostatic Hyperplasia, Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡